A new economic environment is demanding change in biopharma. Rising costs of New Science and patient care coupled with a slow embrace of technology has the industry at an inflection point where companies must do the impossible:
Produce and deliver more effective, affordable, personalized treatments—all while adapting to new ways of working at crisis pace.
All the while, technology giants are looking to replace industry incumbents. Add in a growing health equity gap accelerated by social injustice and mid-pandemic uncertainty – biopharma companies need new solutions to navigate all of this.
The answer? Novel technology—the same technology used by those giants looking to breakthrough—coupled with New Science, human ingenuity and an unwavering commitment to improving patient outcomes.